Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Mind Cure Health Inc. (C:MCUR)

Business Focus: Biotechnology & Medical Research

Sep 23, 2021 03:30 am ET
MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers
MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform
Sep 22, 2021 03:30 am ET
MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF
VANCOUVER, BC, Sept. 22, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it has been included in the new AdvisorShares Psychedelics ETF, trading on the NYSE Arca under the ticker symbol "PSIL" (the "ETF").
Sep 17, 2021 03:30 am ET
MINDCURE to Participate in Maxim Group LLC's Advances in Mental Health Virtual Conference
VANCOUVER, BC, Sept. 17 , 2021 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two panel sessions at the Advances in Mental Health Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on  September 22, 2021.
Sep 17, 2021 03:30 am ET
MINDCURE to Participate in Maxim Group LLC's Advances in Mental Health Virtual Conference
VANCOUVER, BC, Sept. 17 , 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two panel sessions at the Advances in Mental Health Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on  September 22, 2021.
Sep 16, 2021 03:30 am ET
MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry
VANCOUVER, BC, Sept. 16, 2021 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of digital therapies.
Sep 16, 2021 03:30 am ET
MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry
VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of digital therapies.
Sep 09, 2021 03:30 am ET
MINDCURE Announces Platinum Sponsorship of the 2021 SANA Symposium
As the official meeting of the Psychedelic Medicine Association, this conference will connect mental health professionals with promising research and breakthrough treatment therapies from the emerging field.
Sep 09, 2021 03:30 am ET
MINDCURE Announces Platinum Sponsorship of the 2021 SANA Symposium
As the official meeting of the Psychedelic Medicine Association, this conference will connect mental health professionals with promising research and breakthrough treatment therapies from the emerging field.
Sep 08, 2021 03:30 am ET
MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
VANCOUVER, BC, Sept. 8, 2021 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held from September 13-15, 2021.
Sep 08, 2021 03:30 am ET
MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
VANCOUVER, BC, Sept. 8, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held from September 13-15, 2021.
Aug 31, 2021 08:37 pm ET
MINDCURE Announces Financial Results for Fiscal 2021
VANCOUVER, BC, Aug. 31, 2021 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced its financial results for the three and twelve months ended May 31, 2021. All amounts are stated in Canadian dollars unless otherwise indicated.  
Aug 31, 2021 08:37 pm ET
MINDCURE Announces Financial Results for Fiscal 2021
VANCOUVER, BC, Aug. 31, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced its financial results for the three and twelve months ended May 31, 2021. All amounts are stated in Canadian dollars unless otherwise indicated.  
Aug 26, 2021 03:30 am ET
MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America
With its minimum viable product (MVP) release on schedule and on budget, MINDCURE will work with its clinical partners to refine the application before full commercial deployment in Q1 2022.
Aug 26, 2021 03:30 am ET
MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America
With its minimum viable product (MVP) release on schedule and on budget, MINDCURE will work with its clinical partners to refine the application before full commercial deployment in Q1 2022.
Aug 19, 2021 08:17 am ET
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as...
Aug 10, 2021 03:30 am ET
MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team
Dr. Weingardt, a clinical psychologist and previously a Senior Clinical Director at Pear Therapeutics will guide MINDCURE's digital therapeutics technology (DTx) platform, iSTRYM, through near-term commercial deployment
Aug 10, 2021 03:30 am ET
MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team
Dr. Weingardt, a clinical psychologist and previously a Senior Clinical Director at Pear Therapeutics will guide MINDCURE's digital therapeutics technology (DTx) platform, iSTRYM, through near-term commercial deployment
Aug 04, 2021 03:30 am ET
MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor
The recipient of numerous human rights and leadership awards, Mr. White will assist MINDCURE on its mission to revolutionize mental health treatments through the development and scaling of science-backed psychedelic medicines globally.
Aug 04, 2021 03:30 am ET
MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor
The recipient of numerous human rights and leadership awards, Mr. White will assist MINDCURE on its mission to revolutionize mental health treatments through the development and scaling of science-backed psychedelic medicines globally.
Jul 27, 2021 03:30 am ET
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.
Jul 27, 2021 03:30 am ET
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.
Jul 13, 2021 03:30 am ET
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
The company's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine.
Jul 13, 2021 03:30 am ET
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
The company's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine.
Jul 12, 2021 08:30 am ET
MINDCURE Adopts Advance Notice Policy
VANCOUVER, BC, July 12, 2021 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company with respect to nominations of directors to the Company's Board ("Advance Notice Policy").
Jul 12, 2021 08:30 am ET
MINDCURE Adopts Advance Notice Policy
VANCOUVER, BC, July 12, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company with respect to nominations of directors to the Company's Board ("Advance Notice Policy").
Jun 30, 2021 03:30 am ET
Maxim Group Initiates Coverage of Mind Cure Health
VANCOUVER, BC, June 30, 2021 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE.
Jun 17, 2021 03:30 am ET
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development unlocks the company's protocol distribution platform in time for iSTRYM's clinical MVP launch in Q3 2021.
Jun 17, 2021 03:30 am ET
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development unlocks the company's protocol distribution platform in time for iSTRYM's clinical MVP launch in Q3 2021.
Jun 03, 2021 03:30 am ET
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine while ensuring consistent dosing and reliable results.
May 20, 2021 03:30 am ET
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization
May 19, 2021 03:30 am ET
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor
Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children's Hospital and professor at Harvard Medical School, will assist on MINDCURE's digital technology, data optimization and patient data security within iSTRYM, its psychedelic digital therapeutics platform
Apr 29, 2021 08:45 am ET
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
MINDCURE is well-positioned to capitalize on its near-term revenue strategy, complete beta testing and launch of digital therapeutic tool iSTRYM and further its research into psychedelics
Apr 27, 2021 07:45 am ET
MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM
Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate psychedelic-assisted psychotherapy into their lives
Apr 22, 2021 08:45 am ET
MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors
Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO at BMO Wealth Management, has significant expertise in corporate governance, human resources and operational risk management
Apr 21, 2021 08:45 am ET
MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
LUCID's technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback
Apr 14, 2021 03:30 am ET
MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment
Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE's Commercial Focus And Strategic Partnerships
Apr 13, 2021 03:30 am ET
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform
Utilizing Speak Ai's technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
Apr 08, 2021 03:30 am ET
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada's Section 56(1) Exemption
Apr 07, 2021 07:07 am ET
Emerging Markets Report: The Mushroom Movement
A short while ago we introduced our readers to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) which is “focused on finding new ways to treat the profound distress of a world suffering from a mental health crisis” and pursuing “the...
Mar 31, 2021 07:45 am ET
MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitio
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281
Mar 30, 2021 08:30 am ET
March Psychedelic Capital Investigates Ethical IP and Financial Instruments
Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund, the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic Capital.
Mar 23, 2021 07:07 am ET
Emerging Markets Report: A Psychedelic Solution to a National Crisis
Today’s featured company is emerging in a new lane of health care that we believe could be revolutionary. Please allow us to introduce Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH). Let’s start with the Company mission statement:...
Mar 19, 2021 07:45 am ET
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
The award-winning professor and psychology Ph.D. is an expert in translating psychological research and science into Artificial Intelligence backed real-world solutions
Mar 15, 2021 07:45 am ET
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has successfully scaled several high-growth companies
Mar 09, 2021 02:30 am ET
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform
Mar 04, 2021 02:30 am ET
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
Mar 03, 2021 02:30 am ET
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
The Company expects to have ibogaine manufactured and in use for research by Q4.
Feb 22, 2021 02:30 am ET
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
The appointment further strengthens the Company's leadership position in the use of technology to develop psychedelic-related treatments
Feb 22, 2021 02:30 am ET
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
The appointment further strengthens the Company's leadership position in the use of technology to develop psychedelic-related treatments
Feb 18, 2021 02:30 am ET
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first items in a line of original supplements, including Reishi Energy, Lion's Mane Focus, Turkey Tail Immunity, and Teen, available for purchase.
Feb 18, 2021 02:30 am ET
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first items in a line of original supplements, including Reishi Energy, Lion's Mane Focus, Turkey Tail Immunity, and Teen, available for purchase.
Feb 17, 2021 06:48 pm ET
Mind Cure Comments on Recent Promotional Activity
VANCOUVER, BC, Feb. 17, 2021 /CNW/ - Mind Cure Health Inc. ("Mind Cure" or the "Company") (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) has been asked by OTC Markets Group Inc. ("OTC Markets") to comment on recent promotional activity concerning its common shares traded on the OTCQB.
Feb 17, 2021 06:48 pm ET
Mind Cure Comments on Recent Promotional Activity
VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - Mind Cure Health Inc. ("Mind Cure" or the "Company") (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) has been asked by OTC Markets Group Inc. ("OTC Markets") to comment on recent promotional activity concerning its common shares traded on the OTCQB.
Feb 17, 2021 02:30 am ET
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure.
Feb 17, 2021 02:30 am ET
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure.
Feb 16, 2021 02:30 am ET
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE's PsyCollage tool to drive decision-making for drug lead optimization and assist in the discovery of target receptors.
Feb 16, 2021 02:30 am ET
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE's PsyCollage tool to drive decision-making for drug lead optimization and assist in the discovery of target receptors.
Feb 11, 2021 07:30 am ET
MINDCURE Announces Listing of Warrants
Warrants will be listed for trading on CSE under the symbol "MCUR.WT", starting Feb. 11, 2021 .
Feb 10, 2021 08:42 am ET
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Jan 26, 2021 07:28 am ET
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
MINDCURE's proprietary line of integrative medicines, intended to balance the immune system and neurochemicals before and after psychedelic therapy, to be finalized in Q1
Jan 22, 2021 10:50 am ET
IIROC Trade Resumption - MCUR
VANCOUVER, BC, Jan. 22, 2021 /CNW/ - Trading resumes in:
Jan 22, 2021 10:33 am ET
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Jan 21, 2021 02:37 pm ET
Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Jan 21, 2021 02:01 pm ET
IIROC Trading Halt - MCUR
VANCOUVER, BC, Jan. 21, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 21, 2021 11:50 am ET
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index
Jan 21, 2021 11:50 am ET
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index
Jan 12, 2021 02:30 am ET
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure's digital therapeutics platform.
Jan 12, 2021 02:30 am ET
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure's digital therapeutics platform.
Jan 06, 2021 02:30 am ET
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
Mind Cure's iSTRYM (pronounced eye-stream) has been designed to warehouse the largest collection of psychedelic research and ongoing mental optimization data. With machine learning deployed, iSTRYM will provide greater speed to Mind Cure's research team, richer data to health professionals and clients, as well as a hub of protocol and procedural information for psychedelic practitioners worldwide.
Jan 06, 2021 02:30 am ET
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
Mind Cure's iSTRYM (pronounced eye-stream) has been designed to warehouse the largest collection of psychedelic research and ongoing mental optimization data. With machine learning deployed, iSTRYM will provide greater speed to Mind Cure's research team, richer data to health professionals and clients, as well as a hub of protocol and procedural information for psychedelic practitioners worldwide.
Dec 31, 2020 02:30 am ET
Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
Mind Cure's nootropic products are set to launch across 17 locations within North America starting Feb, 2021.
Dec 31, 2020 02:30 am ET
Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
Mind Cure's nootropic products are set to launch across 17 locations within North America starting Feb, 2021.
Dec 29, 2020 02:30 am ET
Mind Cure Announces Novel Supplement Product to Address Teen Wellness
Mind Cure announces all-natural supplement designed to relieve restlessness and nervousness in teens, to be released in early 2021
Dec 29, 2020 02:30 am ET
Mind Cure Announces Novel Supplement Product to Address Teen Wellness
Mind Cure announces all-natural supplement designed to relieve restlessness and nervousness in teens, to be released in early 2021
Dec 10, 2020 02:30 am ET
Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021 
Dec 10, 2020 02:30 am ET
Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021 
Dec 09, 2020 03:07 pm ET
Mind Cure Health Inc. Announces Participation in the Benzinga Global Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - December 9, 2020) - Mind Cure Health Inc. (CSE: MCUR) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2020. We invite our shareholders and all interested parties to explore small cap investment opportunities through two days of networking, dealmaking and discovery.
Dec 08, 2020 02:30 am ET
Mind Cure Announces its Research Program with Psychedelic Compounds
The company is focused on investigating Psilocibin, Ketamine and Ibogaine compounds to be used in the treatment of physical and psychological pain and related mental health illnesses
Dec 08, 2020 02:30 am ET
Mind Cure Announces its Research Program with Psychedelic Compounds
The company is focused on investigating Psilocibin, Ketamine and Ibogaine compounds to be used in the treatment of physical and psychological pain and related mental health illnesses
Dec 02, 2020 02:30 am ET
Mind Cure Announces Eligibility for DTC Trading
Mind Cure's common shares now able to meet US demand with more simplicity
Dec 02, 2020 02:30 am ET
Mind Cure Announces Eligibility for DTC Trading
Mind Cure's common shares now able to meet US demand with more simplicity
Dec 01, 2020 07:30 am ET
Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
The new visionary CEO to execute her psychedelics strategy for transformational mental health care
Dec 01, 2020 07:30 am ET
Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
The new visionary CEO to execute her psychedelics strategy for transformational mental health care
Nov 19, 2020 11:45 am ET
Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering
In excess of $5 Million cash on hand to evaluate new product candidates including psychedelic product research opportunities and support existing product line launch
Nov 13, 2020 06:57 am ET
Mind Cure Announces Non-Brokered Private Placement of $3 Million
The Company has received subscription commitments in the aggregate amount of $3 million
Nov 10, 2020 02:30 am ET
Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer
An experienced life sciences doctor, researcher, inventor and entrepreneur, Dr. Hartwell will lead Mind Cure's research efforts as it explores a range of new psychoactive substances and their therapeutic benefits
Nov 10, 2020 02:30 am ET
Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer
An experienced life sciences doctor, researcher, inventor and entrepreneur, Dr. Hartwell will lead Mind Cure's research efforts as it explores a range of new psychoactive substances and their therapeutic benefits
Oct 21, 2020 03:30 am ET
Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health
Mind Cure is accelerating its move into the mental health technology space with proprietary platform
Oct 15, 2020 08:10 am ET
Mind Cure Announces Geoff Belair as Chief Technology Officer
Fintech executive has deep experience in developing and operating new and innovative technologies in highly regulated industries
Oct 13, 2020 03:30 am ET
Mind Cure Announces Addition of Neuroscientist Dr. Wolfram Tetzlaff to Scientific Advisory Board
Dr. Tetzlaff, a world-renowned researcher and scientist with decades of experience in neuroscience, is known for his innovative and multidisciplinary approach
Oct 08, 2020 03:30 am ET
Health and Wellness Industry Tastemaker Jon Bier Joins Mind Cure's Advisory Board
Mr. Bier is a communications and strategy expert who has played a key role in building brands such as Four Sigmatic and WHOOP
Oct 07, 2020 03:30 am ET
Mind Cure Welcomes Dr. Jason Wallach to Scientific Advisory Board
Known globally for his industry research and expertise, Dr. Wallach will help to drive new areas of research and product development at Mind Cure
Oct 06, 2020 03:30 am ET
Mind Cure Welcomes Award-Winning Journalist and Science Researcher Hamilton Morris to Advisory Board
A trusted resource for millions worldwide as a psychoactive substances' expert, Mr. Morris is at the forefront of the psychedelic movement
Oct 01, 2020 09:12 am ET
Dr. Dan Engle Joins Mind Cure's Advisory Board
The world-renowned transformative medicine expert will contribute towards Mind Cure's work in the realm of psychedelic research, treatment and integration
Sep 29, 2020 07:45 am ET
Mind Cure Announces Kelsey Ramsden as new Chief Operating Officer
The company bolsters its executive team with the addition of an industry leader and experienced entrepreneur
Sep 24, 2020 07:45 am ET
Mind Cure adds Alain Roy as a product development specialist
Mind Cure makes addition to its teamMoonbeam Functional Mushrooms in final testing stage
Sep 23, 2020 07:45 am ET
Mind Cure Receives Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
Health Canada Issues Natural Product Number Licenses to Mind Cure
Sep 21, 2020 08:06 am ET
Mind Cure announces commencement of trading on the CSE
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Sep 17, 2020 11:30 am ET
Mind Cure Announces Closing of Oversubscribed Upsized Initial Public Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./
Sep 16, 2020 04:05 pm ET
CSE Bulletin: Appointment of Market Maker - Mind Cure Health Inc. (MCUR)
Toronto, Ontario--(Newsfile Corp. - September 16, 2020) - Effective Monday, September 21th, pending the assignment of a permanent Market Maker, Independent Trading Group will be the temporary Market Maker responsible for the Guaranteed Fill volume and automatic execution of odd lots for the symbol below. The CSE is now accepting applications for a permanent Market Maker.
Sep 16, 2020 12:28 pm ET
CSE Bulletin: New Listing - Mind Cure Health Inc. (MCUR)
Toronto, Ontario--(Newsfile Corp. - Le 16 septembre/September 2020) - The common shares of Mind Cure Health Inc. have been approved for listing on the CSE.